Yu Chengpeng, Wan Haiting, Shan Renfeng, Wen Wu, Li Jianfeng, Luo Daya, Wan Renhua
Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China.
Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanchang University, Nanchang, China.
J Cancer. 2019 Jul 8;10(17):4009-4016. doi: 10.7150/jca.27529. eCollection 2019.
: MicroRNAs are small non-coding RNAs containing 18-22 nucleotides which play a role in RNA silencing and post-transcriptional regulation of their target genes. The MiR-200 family comprises miR-141, miR-200a, miR-200b, miR-200c and miR-429. Increasing evidence indicates that miR-200 microRNAs play a role in cancer metastasis. For example, miR-200 microRNAs were reported to influence the prognosis in colorectal cancer patients by regulating the expression of genes related to the epithelial-mesenchymal transition. Previous studies have shown that the high expression of miR-200 microRNAs has an impact on the overall survival and Relapse-free Survival of CRC patients. However, the study results were inconsistent. : Data from a total of 1882 patients from 9 studies was included in the meta-analysis. Poorer Relapse-free Survival (RFS) was observed in patients with high expression levels of miR-200 microRNAs (HR=1.13, 95% CI 1.04-1.23). Additionally, subgroup analysis of sample types revealed a significant association between higher expression of the miR-200 family in the plasma and poorer OS (HR=1.23, 95% CI 1.08-1.41) and RFS (HR=2.39, 95% CI 1.20-4.77), which indicates that the miR-200 family can be used as an easily detectable biomarker for evaluation of the prognosis of patients with colorectal cancer. : High expression levels of miR-200 microRNAs were associated with poor clinical outcomes in colorectal cancer patients. The miR-200 family can therefore potentially serve as a prognostic biomarker. Further studies should be performed to verify the clinical utility of the miR-200 family in colorectal cancer.
微小RNA是一类包含18 - 22个核苷酸的小型非编码RNA，在RNA沉默及其靶基因的转录后调控中发挥作用。MiR - 200家族包括miR - 141、miR - 200a、miR - 200b、miR - 200c和miR - 429。越来越多的证据表明，miR - 200微小RNA在癌症转移中起作用。例如，据报道miR - 200微小RNA通过调节与上皮 - 间质转化相关的基因表达来影响结直肠癌患者的预后。先前的研究表明，miR - 200微小RNA的高表达对结直肠癌患者的总生存期和无复发生存期有影响。然而，研究结果并不一致。：荟萃分析纳入了来自9项研究的总共1882例患者的数据。在miR - 200微小RNA高表达水平的患者中观察到较差的无复发生存期（RFS）（HR = 1.13，95% CI 1.04 - 1.23）。此外，样本类型的亚组分析显示，血浆中miR - 200家族的高表达与较差的总生存期（OS）（HR = 1.23，95% CI 1.08 - 1.41）和RFS（HR = 2.39，95% CI 1.20 - 4.77）之间存在显著关联，这表明miR - 200家族可作为一种易于检测的生物标志物用于评估结直肠癌患者的预后。：miR - 200微小RNA的高表达水平与结直肠癌患者的不良临床结局相关。因此，miR - 200家族有可能作为一种预后生物标志物。应进行进一步研究以验证miR - 200家族在结直肠癌中的临床应用价值。
